FDA expands approval of breast cancer drug Kisqali
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
FDA expands approval of breast cancer drug Kisqali to earlier stage patients
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients will be able to receive it.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive,
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early breast cancer. | An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis' Kisqali and Eli Lilly's Verzenio in early breast cancer.
Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.
FDA Expands Use of Breast Cancer Drug Kisqali
The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph nodes] disease, is a pivotal moment in improving our approach to care,” said Dr.
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a woman who took the drug while it was in clinical trials and is now cancer free.
The American Journal of Managed Care2d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
Medscape22h
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase ...
Pharmabiz15h
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...
pharmaphorum1d
Lilly on alert as new Kisqali approval threatens Verzenio
Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over ...